Univariate and multivariable Cox regression analyses for late respiratory infections after day 100 after BCMA–directed CAR T-cell therapy
| Variable . | Univariate HR . | 95% CI . | P value . | Multivariable HR . | 95% CI . | P value . |
|---|---|---|---|---|---|---|
| Lines of treatment >5 | 0.77 | 0.26–2.31 | .646 | — | — | — |
| Previous autologous hematopoietic cell transplantation | 0.86 | 0.29–2.57 | .790 | — | — | — |
| CRS diagnosis | 0.60 | 0.14–2.58 | .496 | 0.506 | 0.17--1.51 | .223 |
| Tocilizumab administration | 0.80 | 0.26–2.40 | .686 | — | — | — |
| ICANS diagnosis | 1.13 | 0.24–5.36 | .881 | — | — | — |
| Corticosteroid administration | 1.17 | 0.38–3.57 | .787 | — | — | — |
| CD4 T-cell ≤ 200 cells/uL (day 30-100) | 1.21 | 0.36–4.07 | .757 | — | — | — |
| IgG ≤400 mg/dL (day 30-100) | 5.03 | 0.66–38.24 | .119 | 6.06 | 1.05–35.08 | .044 |
| Early respiratory infection | 2.74 | 0.81–9.23 | .105 | 2.95 | 1.01–8.63 | .048 |
| Variable . | Univariate HR . | 95% CI . | P value . | Multivariable HR . | 95% CI . | P value . |
|---|---|---|---|---|---|---|
| Lines of treatment >5 | 0.77 | 0.26–2.31 | .646 | — | — | — |
| Previous autologous hematopoietic cell transplantation | 0.86 | 0.29–2.57 | .790 | — | — | — |
| CRS diagnosis | 0.60 | 0.14–2.58 | .496 | 0.506 | 0.17--1.51 | .223 |
| Tocilizumab administration | 0.80 | 0.26–2.40 | .686 | — | — | — |
| ICANS diagnosis | 1.13 | 0.24–5.36 | .881 | — | — | — |
| Corticosteroid administration | 1.17 | 0.38–3.57 | .787 | — | — | — |
| CD4 T-cell ≤ 200 cells/uL (day 30-100) | 1.21 | 0.36–4.07 | .757 | — | — | — |
| IgG ≤400 mg/dL (day 30-100) | 5.03 | 0.66–38.24 | .119 | 6.06 | 1.05–35.08 | .044 |
| Early respiratory infection | 2.74 | 0.81–9.23 | .105 | 2.95 | 1.01–8.63 | .048 |